New data has been revealed in support of Novartis’ Cosentyx (secukinumab) in the treatment of moderate-to-severe plaque psoriasis, demonstrating the drug delivered greater quality of life improvements compared to Janssen’s Stelara (ustekinumab) after 16 weeks of treatment.
The data showed that 68.4% of patients receiving Cosentyx experienced no impact of skin disease on their quality of life after 16 weeks of treatment, compared to 55.9% of those receiving Stelara.
![[column] Toekomst tijdschriften glanst als nooit tevoren](https://www.pharmamarketeer.nl/wp-content/uploads/2024/12/happy-couple-in-t-shirts-reading-newspaper-while-h-2024-11-10-00-13-23-utc-1-80x60.jpg)
![[column] MarketingAffairs 17: Marketing als oplossing](https://www.pharmamarketeer.nl/wp-content/uploads/2024/12/asian-seo-manager-writing-on-glass-with-illustrati-2024-11-17-23-11-51-utc-1-80x60.jpg)
